TrialNeuro-oncology2020
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Marianne Schell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled itcites it